Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.
Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.
Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.
Jyoti D. Patel, MD, discusses immunotherapy combinations for patients with advanced nonsquamous non–small cell lung cancer.
Everett E. Vokes, MD, discusses remaining questions in stage III non–small cell lung cancer following the PACIFIC results.
Jeremy Segal, MD, PhD, discusses pathologic considerations in non–small cell lung cancer and the evolving role of molecular testing.
Everett E. Vokes, MD, discusses unanswered questions from the phase III PACIFIC trial in stage III non–small cell lung cancer.
Jyoti D. Patel, MD, FASCO, discusses the implications of genetic testing, the lasting impact of the KEYNOTE and IMpower trials in patients with advanced nonsquamous non–small cell lung cancer, and considerations for treatment selection.